# Filing Detail

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001178913-25-001065
Filing Date
2025-03-27
Accepted
2025-03-27 08:30:11
Documents
6
Period of Report
2025-03-27

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 6-K | zk2532931.htm | 6-K | 11007
2 | EXHIBIT 99.1 | exhibit_99-1.htm | EX-99.1 | 26308
3 |  | image00001.jpg | GRAPHIC | 70904
4 |  | image1.jpg | GRAPHIC | 68417
5 |  | image00003.jpg | GRAPHIC | 193724
6 |  | image3.jpg | GRAPHIC | 242583
| Complete submission text file | 0001178913-25-001065.txt |  | 831588

Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

EIN.: 813676773 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38807 | Film No.: 25775451
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)